A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 32,197 shares of TRVI stock, worth $88,541. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,197
Previous 21,151 52.22%
Holding current value
$88,541
Previous $63,000 69.84%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.58 - $3.51 $28,498 - $38,771
11,046 Added 52.22%
32,197 $107,000
Q2 2024

Aug 14, 2024

BUY
$2.44 - $3.36 $51,608 - $71,067
21,151 New
21,151 $63,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $160M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Mirae Asset Global Etfs Holdings Ltd. Portfolio

Follow Mirae Asset Global Etfs Holdings Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Etfs Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Etfs Holdings Ltd. with notifications on news.